Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective (vol 43, pg S1, 2021)

被引：0

作者：

Salvino, M. A. ^{[1
,2
]}

Bonfim, C. ^{[3
]}

Calado, R. T. ^{[4
]}

Kim, H. ^{[5
]}

Bertinato, J. F. ^{[5
]}

Scheinberg, P. ^{[6
]}

机构：

[1] Univ Fed Bahia UFBA, HUPES, Salvador, BA, Brazil

[2] Hosp Sao Rafael, Inst DOr Ensino & Pesquisa IDOR, Salvador, BA, Brazil

[3] Univ Fed Parana UFPR, Dept Hematol, Blood & Marrow Transplantat Unit, Hosp Clin, Curitiba, PR, Brazil

[4] Univ Sao Paulo, FMRP, Dept Med Imaging Haematol & Clin Oncol, Curitiba, PR, Brazil

[5] Novartis Biociencias SA, Sao Paulo, SP, Brazil

[6] Beneficencia Portuguesa Sao Paulo BP, Div Hematol, Sao Paulo, SP, Brazil

来源：

HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2022年 / 44卷 / 02期

关键词：

D O I：

10.1016/j.htct.2022.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 1

页数：1

共 35 条

[21] First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective
Hu, Xiaohan
Hay, Joel W.
[J]. LUNG CANCER, 2018, 123 : 166 - 171
[22] Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective
Li, Wei
Wan, Li
Zhang, Jiangyan
[J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (06) : 293 - 301
[23] Cost-effectiveness analysis of TNF-α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system (vol 23, pg S7, 2010)
Calzavara-Pinton, Piergiacomo
[J]. DERMATOLOGIC THERAPY, 2010, 23 (04) : 434 - 434
[24] Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
Ping-Tee Tan
Mohamed Ismail Abdul Aziz
Fiona Pearce
Wan-Teck Lim
David Bin-Chia Wu
Kwong Ng
[J]. BMC Cancer, 18
[25] Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
Tan, Ping-Tee
Aziz, Mohamed Ismail Abdul
Pearce, Fiona
Lim, Wan-Teck
Wu, David Bin-Chia
Ng, Kwong
[J]. BMC CANCER, 2018, 18
[26] Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
Zhou, Kexun
Shu, Pei
Zheng, Hanrui
Li, Qiu
[J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
[27] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Fernandes, R. A.
Schiola, A.
[J]. VALUE IN HEALTH, 2009, 12 (03) : A42 - A42
[28] Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives
Cheng, Shuqiao
Pei, Rui
Li, Jianhuang
Li, Bin
Tang, Lanhua
Yin, Tao
Liu, Shao
[J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
[29] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
Chen Zhu
Gang Han
Bin Wu
[J]. BMC Health Services Research, 23 (1)
[30] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
Zhu, Chen
Han, Gang
Wu, Bin
[J]. BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)

← 1 2 3 4 →